Like all siblings, Robin and Jessica McIntyre have had their share of battles yet they've always been close. And that bond grows stronger as they contend with the exceptional cruelties life has visited upon their family. "I have probably lived more of my life than I have left," said Robin matter-of-factly. Robin carries the genetic mutation for early onset Alzheimer's disease. Barring a major medical breakthrough, her chances of getting the disease are 100%.
A devastating chronic neurodegenerative disease, Alzheimer's disease (AD) currently affects around 5.5 million people in the United States alone. Causing progressive mental deterioration, it ultimately advances to impact basic bodily functions such as walking and swallowing. Looking for a way to help, researchers at the University of Bari and Istituto Nazionale di Fisica Nucleare in Italy have developed new machine learning AI technology that may help identify Alzheimer's a decade before doctors usually can, by way of non-invasive MRI brain scans. An early diagnosis -- before any of the symptoms a doctor might recognize become apparent -- could give patients a chance to make changes to their lifestyle which may slow Alzheimer's progression. "We used this cohort to feed [our] artificial intelligence, then an independent test of about 148 subjects -- including controls, Alzheimer's disease and mild cognitive impairment (MCI) subjects -- was performed.
When Ken Dodson starting having memory issues eight years ago, he and his wife suspected a possible brain tumor, but doctors brushed his symptoms off as depression. Just a week before Dodson turned 30, doctors delivered a devastating diagnosis of early-onset Alzheimer's disease, giving him only seven to 10 "good years." "I almost am married to two different people," Nikki Dodson told Fox 2 Detroit. "I have my husband, and I have the person I care for." The couple, who were married for nine years before his diagnosis and have three children together, has vowed to stay together.
There is no good evidence that a nutrient drink being sold online in the UK to "help" people with early Alzheimer's actually slows the disease, say experts. Latest trial results in patients who took Souvenaid did not find it preserves memory and thinking. The authors say in Lancet Neurology that bigger studies are needed to show if the product can work as hoped. And consumers should be aware that the £3.49 per bottle drink "is not a cure". Manufacturer Nutricia says its drink should only be taken under the direction of a doctor, specialist nurse or pharmacist.